An interventional study of aspirin treatment and Aspirin placebo in Moyamoya Disease, Moyamoya Syndrome and Aspirin, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.
Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is one of 3 that started in 2026, is one of 3 with no phase, and was the 12th registered.
62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.
Browse Moyamoya Disease studies →10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–70
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Beijing Tiantan Hospital · Sites in China
Ages 18–60 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–60
Beijing Tiantan Hospital · Sites in China
Healthy volunteers
By country, each count listing its studies:
Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 724 is above the median of 73 across 32 interventional studies indexed under Moyamoya Disease.
Median enrollment 328 across the 3 interventional studies, 350 across the 11 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 490 studies on the registry; 294 are open to participants now.
2 of the studies in Moyamoya Disease by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05332756Beijing Tiantan HospitalLong-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA) | 2026-11-30 |
| NCT07517354Beijing Tiantan HospitalFamily-Based Moyamoya Susceptibility and Early Detection | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease characterized by progressive stenosis or occlusion at the terminal portion of the internal carotid artery, with formation of an abnormal vascular network at the base of the brain. Moyamoya syndrome (MMS) has the same cerebrovascular imaging and clinical manifestations as moyamoya disease, but it is accompanied by other systemic comorbidities. Moyamoya disease and moyamoya syndrome are collectively referred to as moyamoya-like cerebrovascular disease. They are highly prevalent in East Asia, and China has a large patient population. In 2018, the incidence was 1.6 per 100,000 person-years, and the disease is a major cause of stroke in children, adolescents, and young adults [1]. This group of diseases often causes severe complications such as stroke and cognitive impairment, leading to poor prognosis and reduced ability to live independently [2]. Among patients who do not receive effective treatment, the risk of severe neurological deficit or death is as high as 75%, and approximately 60% of patients with moyamoya disease develop cognitive impairment [3]. Therefore, moyamoya disease (moyamoya syndrome) is a major health problem that seriously affects the health of the Chinese population.
At present, several urgent problems remain in the clinical diagnosis and treatment of moyamoya disease (moyamoya syndrome). First, the epidemiological characteristics and disease susceptibility of this condition in the Chinese population are not yet fully clear. Second, reliable clinical assessment tools and standardized risk prediction models for moyamoya disease are lacking, and there is still no clear basis for identifying which patients need timely intervention. Third, a systematic precision treatment pathway for moyamoya disease has not yet been established, and high-quality evidence is still lacking regarding the role of pharmacological and physical therapy in delaying disease progression. Therefore, systematic research to clarify the efficacy of different treatment approaches in moyamoya disease is of great significance for promoting the establishment of an integrated diagnostic and therapeutic system for this disease.
[Add a paragraph introducing ischemic conditioning and its role in stroke and MMD.] Systematic treatment is an important means to improve the prognosis of moyamoya disease. Current major treatment options include revascularization surgery and pharmacological therapy. Previous studies have shown that revascularization surgery can improve cerebral blood flow and reduce the risk of stroke; however, for asymptomatic or early-stage patients, surgery is not the only option [4]. In terms of pharmacological therapy, nonsurgical treatments such as antiplatelet therapy and intensive lipid-lowering therapy may delay disease progression, but high-quality clinical evidence remains lacking. In addition, emerging physical therapies such as ischemic conditioning have been shown to improve the tolerance of brain tissue to ischemia and have demonstrated potential therapeutic value in patients with stroke [5]. However, the safety and efficacy of these treatment approaches in patients with moyamoya disease require further study and validation.
Therefore, this study proposes to conduct a multicenter, prospective randomized controlled clinical trial to systematically evaluate the efficacy and safety of aspirin therapy and ischemic conditioning therapy in delaying the progression of moyamoya disease, and to provide evidence-based support for nonsurgical treatment strategies for patients with moyamoya disease.
[The following content was moved from the study rationale section and should be integrated with the research background.] Even when patients with moyamoya disease (moyamoya syndrome) have not yet developed definite symptoms of cerebral infarction, their cerebral hemodynamics may already be in a compensated or critical state. They are often prone to nonspecific symptoms such as headache and dizziness, subjective cognitive decline, and TIA attacks, and they have a potential risk of progression to symptomatic stroke. Microembolus formation and vascular endothelial dysfunction may further reduce flow reserve and aggravate hypoperfusion, thereby leading to adverse events. For such mildly affected patients, early intervention has important clinical value for delaying disease progression and preventing cerebrovascular events.
Aspirin irreversibly inhibits cyclooxygenase-1 and blocks thromboxane A2 production, thereby inhibiting platelet aggregation. In the pathological process of moyamoya disease (moyamoya syndrome), microcirculatory changes and vascular intimal injury may activate platelets and promote microthrombus formation, which may aggravate ischemia-induced stroke. Therefore, aspirin may reduce the risk of ischemic events by inhibiting platelet aggregation. Ischemic conditioning is a noninvasive physical therapy that activates systemic endogenous protect
History of any form of intracranial hemorrhage, including subarachnoid hemorrhage, intracerebral hemorrhage, intraventricular hemorrhage, etc.; history of symptomatic ischemic stroke; frequent (TIAs) before enrollment, defined as ≥3 episodes within 7 days; or history of epileptic seizures.
Concomitant cerebrovascular diseases that may significantly affect perioperative risk or outcome assessment, such as intracranial aneurysms requiring concomitant treatment, cerebral arteriovenous malformations, arteriovenous fistulas, or other relevant cerebrovascular lesions.
History of severe traumatic brain injury, brain tumor, encephalitis, meningitis, or other inflammatory diseases of the central nervous system; other major intracranial diseases; any prior invasive intracranial treatment; or history of cranial radiotherapy.
Planned cerebral revascularization surgery within 3 months. Severe cardiac dysfunction ( \<50% or [NYHA] class III-IV), hepatic dysfunction ( [ALT] or aspartate aminotransferase [AST] >2 times the ), or renal dysfunction (serum creatinine >1.5 times the upper limit of normal); major systemic diseases such as unstable angina, acute coronary syndrome, asthma, or (COPD); severe noncardiovascular comorbidities with an expected survival of \<1 year; or any other serious comorbidity considered by the investigator to significantly increase study-related risk.
to aspirin, including:
Contraindications to remote ischemic conditioning (RIC), including:
Requirement for anticoagulant therapy, including conditions such as atrial fibrillation, prosthetic heart valves, known or suspected endocarditis, venous thrombosis, or other diseases requiring anticoagulation; or use of heparin or oral anticoagulants within 10 days before enrollment.
Pregnancy, suspected pregnancy (defined as a positive pregnancy test in a woman of who has not used effective ), or breastfeeding.
Conditions that may interfere with completion of key follow-up assessments, such as severe cognitive impairment or psychiatric disorders resulting in inability to cooperate with study evaluations, or a clear expectation that follow-up cannot be completed.
Current participation in another interventional clinical trial that, in the investigator's judgment, may interfere with assessment of the study outcomes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
aspirin placebo + sham ischemic conditioning procedure
Drug: Aspirin placebo · Device: Sham remote ischemic conditioning
aspirin treatment + sham ischemic conditioning procedure
Drug: aspirin treatment · Device: Sham remote ischemic conditioning
aspirin placebo + ischemic conditioning
Drug: Aspirin placebo · Device: Remote Ischemic Conditioning
aspirin treatment + ischemic conditioning
Drug: aspirin treatment · Device: Remote Ischemic Conditioning
Aspirin will be taken orally every morning for 1 year. To ensure medication adherence, study drugs will be dispensed and regularly recovered for pill counting. Aspirin: 100 mg, orally on an empty stomach in the morning, once daily;
Aspirin placebo will be taken orally every morning for 1 year. To ensure medication adherence, study drugs will be dispensed and regularly recovered for pill counting. Placebo: consistent with aspirin in dosage form, dose, packaging, and appearance; 100 mg, orally on an empty stomach in the morning, once daily.
The first 3 months after randomization will be the intensive phase, during which ischemic conditioning will be completed once daily. Months 4 to 6 after randomization will be the maintenance phase, during which ischemic conditioning will be completed no fewer than 4 times per week, with a maximum of once per day. Real ischemic conditioning procedure group: the ischemic conditioning device will be used once daily, including 5 treatment cycles. After blood pressure is measured in both arms, the upper limit of the bilaterally measured blood pressure will be used as the inflation value. The cuffs on both upper limbs will be inflated and maintained for 5 minutes, followed by deflation for 5 minutes. Each treatment session will last 45 minutes.
The first 3 months after randomization will be the intensive phase, during which sham procedure treatment will be completed once daily. Months 4 to 6 after randomization will be the maintenance phase, during which sham procedure treatment will be completed no fewer than 4 times per week, with a maximum of once per day Sham ischemic conditioning procedure group: the sham ischemic conditioning device will be used once daily, including 5 treatment cycles. The cuffs on both upper limbs will be inflated to 60 mmHg and maintained for 5 minutes, followed by deflation for 5 minutes. Each treatment session will last 45 minutes.
The primary efficacy endpoint event
The primary efficacy endpoint event is disease progression or the occurrence of a cerebrovascular event within 1 year, including transient ischemic attack and cerebral infarction.
Time frame: 1 year
Secondary endpoint events
New vascular events within 1 year, including transient ischemic attack, cerebral infarction, cerebral hemorrhage, myocardial infarction, and vascular death; each new vascular event will also be evaluated independently;
Time frame: 1 year
Secondary endpoint events
Disabling stroke events within 1 year (mRS score \> 1);
Time frame: 1 year
Secondary endpoint events
Occurrence and severity of stroke or transient ischemic attack at 3 months and 1 year; severity will be classified according to an ordered 6-level scale combined with the mRS: fatal stroke / severe nonfatal stroke \[mRS 4 or 5\] / severe nonfatal stroke \[mRS 4 or 5\] / moderate stroke \[mRS 2 or 3\] / mild stroke \[mRS 0 or 1\] / TIA / no stroke-TIA;
Time frame: 3 months and 1 year
Secondary endpoint events
Change in neurological deficit at 3 months, compared with baseline, based on the change in mRS score at the 3-month follow-up;
Time frame: 3 months
Secondary endpoint events
Quality of life at the 3-month and 1-year follow-up visits, assessed using the EQ-5D-5L scale.
Time frame: 3 months and 1 year
Secondary endpoint events
Average monthly frequency of TIA attacks within 1 year.
Time frame: 1 year
Secondary endpoint events
Progression of white matter hyperintensity (WMH) lesions within 1 year
Time frame: 1 year
The safety endpoint event
The safety endpoint event is severe or moderate bleeding within 1 year, as defined by GUSTO, or limb soft-tissue injury, peripheral vascular injury, or deep venous thrombosis related to ischemic conditioning within 1 year.
Time frame: 1 year
Plan to share: No
Start is estimated for Jul 2026; primary completion for Feb 2030, 43 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.